Attralus

Attralus is a biotechnology company focused on developing novel pan-amyloid removal (PAR) therapeutics for the treatment of systemic amyloidosis. They are also developing the world's first amyloidosis-specific diagnostic imaging agent, which aims to improve diagnosis and identify the many patients currently undiagnosed. Attralus believes their PAR approach, targeting the underlying cause of disease, has the potential to transform the treatment paradigm, offering a more comprehensive and effective approach to managing systemic amyloidosis.

The company's team of leading amyloidosis scientists and experts has researched and developed therapeutics for over 25 years, bringing a wealth of experience and deep understanding of the disease to their work. Their mission is to improve the lives of patients with amyloidosis by developing transformational therapeutics that remove toxic amyloid, ultimately leading to improved treatment outcomes for patients.

Attralus is a biotechnology company focused on developing novel pan-amyloid removal (PAR) therapeutics to improve the lives of patients with amyloidosis. They are driven by the unmet need for disease-modifying therapies that can remove amyloid across all stages and types of systemic amyloidosis. Their proprietary PAR technology aims to target and eliminate toxic, disease-causing amyloid in organs and tissues, offering the potential to reverse disease pathology and improve treatment outcomes for patients.

Attralus fosters a culture of scientific innovation and patient-centricity, driven by a team of experienced professionals dedicated to transforming the lives of patients with amyloidosis. The company values collaboration, expertise, and a commitment to addressing the unmet needs of the disease, emphasizing the importance of developing groundbreaking therapeutics and diagnostics that directly tackle the underlying pathology.